Bladder cancer and its signs and symptoms
Our understanding of the molecular mechanisms of tumour development and how tumours spread has continually improved, leading to major breakthroughs that have transformed several aspects of cancer care. Roche’s scientists are pioneers in cancer research, and they continuously investigate innovative and personalised treatment options.
Explore the latest in Roche's research and developments in oncology.
An updated analysis of the NRG/RTOG 9413 trial shows that the benefits of whole pelvic radiotherapy (RT) plus neoadjuvant hormonal therapy (NHT) persist in the long term in patients with intermediate- or high-risk localised prostate cancer.
Patients whose colon cancers are detected by routine screening have fewer postoperative complications than individuals whose cancers are diagnosed outside of a national programme, study findings indicate.
Updated findings from the PACIFIC trial demonstrate a significant improvement in overall survival (OS) with the immune checkpoint inhibitor durvalumab for patients with stage III unresectable non-small-cell lung cancer (NSCLC) that has not progressed after concurrent chemoradiotherapy.
The addition of atezolizumab to chemotherapy has significantly improved both the overall survival (OS) and progression-free survival (PFS) of treatment naïve-patients with extensive-stage small-cell lung cancer (SCLC), results from the IMpower133 trial indicate.
Phase I trial findings suggest that patients with metastatic triple-negative breast cancer (mTNBC) might benefit from treatment with the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab.
The addition of apalutamide to androgen deprivation therapy (ADT) has no detrimental effect on health-related quality of life (HRQoL) in men with nonmetastatic castration-resistant prostate cancer, an analysis of data from the SPARTAN trial shows.
Nanoparticle albumin-bound (nab)-paclitaxel given alongside gemcitabine may offer an alternative to existing regimens for patients with untreated advanced or metastatic cholangiocarcinoma, phase II study findings suggest.
Adjuvant treatment with erlotinib is associated with improved disease-free survival (DFS) versus chemotherapy in Chinese patients with epidermal growth factor receptor (EGFR)-mutated, stage IIIA non-small-cell lung cancer (NSCLC), indicate phase II trial results.
Researchers have developed a radiomic CD8-cell signature that could help predict the immune phenotype of solid tumours and thereby a patient’s clinical response.
The multikinase inhibitor anlotinib is effective and well tolerated in advanced non-small-cell lung cancer (NSCLC) patients who have used at least two prior lines of systemic therapy, phase III trial results suggest.
Most patients being treated in the community setting for advanced nonsquamous non-small-cell lung cancer (NSCLC) do not benefit from the use of broad-based genomic sequencing, suggests a study comparing this approach with routine testing for only epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) alterations
The presence of circulating tumour cells (CTCs) 5 years after the treatment of high-risk, hormone receptor (HR)-positive breast cancer is prognostic for late disease recurrence, research demonstrates.
Phase III trial findings suggest that men who require radical prostatectomy for localised prostate cancer achieve similar functional outcomes at 2 years, regardless of whether they undergo robot-assisted laparoscopic surgery or an open radical retropubic procedure.